Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. The ...

The Paris Olympics have been a showcase not only for athletic ... of using the Olympics to sell products of dubious medical value. French pharmaceutical giant Sanofi came under criticism for promoting ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

IMTOZ trial findings and subsequent approval of Isa-VRd regimen for transplant-ineligible myeloma suggested the combo as a ...